SCHEMBL10085100

SCHEMBL10085100

Cc1ccc2[nH]c(=O)n(C(C)C(=O)O)c(=O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.47
▸ MEN1 O00255 5/20 0.47
▸ KMT2A Q03164 5/20 0.47
▸ KDM4E B2RXH2 4/20 0.47
▸ GAA P10253 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ MAPT P10636 3/20 0.44
▸ PKM P14618 1/20 0.44
▸ DAO P14920 2/20 0.43
▸ MAPK1 P28482 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ GFER P55789 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRG2 P18507 1/20 0.41
▸ GABRB3 P28472 1/20 0.41
▸ GABRA3 P34903 1/20 0.41
▸ GABRA2 P47869 1/20 0.41
▸ THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10085586 1.00 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL10085638 0.85 MEN1 (0.48) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL10085072 0.85 ALDH1A1 (0.41) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL10084832 0.85 ALDH1A1 (0.41) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL19254886 0.85 MEN1 (0.48) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL10084835 0.85 ALDH1A1 (0.44) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL31160837 0.85 FEN1 (0.57) MEN1KMT2ADAOMAPK1
SCHEMBL8134204 0.85 MEN1 (0.40) ALDH1A1MEN1KMT2AMAPK1GABRA1
SCHEMBL10084841 0.84 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AKDM4EGAA
SCHEMBL10085008 0.84 ALDH1A1 (0.49) ALDH1A1MEN1KMT2AKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 ALDH1A1 3536/4885MEN1 1964/4885KMT2A 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback